Novo Nordisk’s Sogroya (somapacitan-beco) Receives the US FDA Approval for Adult Growth Hormone Deficiency
Novo Nordisk Resumes P-III Study of Concizumab for Patients with Hemophilia A and B
Shots:
- The approval is based on REAL 1 study assessing Sogroya (10 mg/ 1.5 mL (6.7 mg/mL) vs PBO for 35wks. in adults patients with growth hormone deficiency
- The US FDA ahs approved the BLA of the therapy for the replacement of endogenous growth hormone in adults with GHD
- Sogroya is a prescription medicine containing GH and is used to treat adults who do not make enough growth hormone. Efficacy and safety in children are not known
Click here to read full press release/ article | Ref: Businessnewswire | Image: Businessnewswire